XORTX Therapeutics Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company focused on developing therapies that target aberrant purine metabolism, xanthine oxidase inhibition, and high serum uric acid levels to treat gout and progressive kidney diseases including autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy, and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2. The company develops proprietary product candidates including XRx-026, a pre-NDA stage oxypurinol-based xanthine oxidase inhibitor for gout; XRx-008, a clinically advanced therapy for progressive kidney disease in ADPKD; XRx-101 for acute kidney injury and uric acid-related complications from respiratory viruses including COVID-19; and XRx-225, a preclinical program for type 2 diabetic nephropathy; alongside uric acid-lowering agents reformulated for hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury covered by U.S. and international patents. Founded in 2012 and headquartered in Calgary, Alberta, Canada, XORTX operates globally with a focus on North American and international markets for rare and prevalent kidney disorders, and recently entered a binding term sheet in October 2025 to acquire the VB4-P5 renal anti-fibrotic therapeutic program—a novel small molecule at the pre-IND stage—from Vectus Biosystems Limited to expand its pipeline for unmet needs in rare and large-market kidney diseases; the company also closed a US$1.1 million registered direct offering in October 2025 and a US$925,000 LIFE public offering in July 2025 to fund ongoing development.
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
XORTX Announces Closing of US$5 Million Public Offering
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
XORTX Announces US$5 Million Public Offering
XORTX Therapeutics Inc. (NASDAQ:XRTX) Short Interest Update
XORTX Confirms Effective Date of Share Consolidation
XORTX Announces Results of Annual and Special Meeting of Shareholders
XORTX Announces Change of Effective Date of Share Consolidation
XORTX Announces Share Consolidation
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
XORTX Initiates IND Preparation for XORLO™ in Gout Program
XORTX Completes USD $114,500 Private Placement
XORTX Completes Non-Brokered Private Placement of Units
XORTX Announces USD $925,000 Private Placement